Ionis begins phase I/II study of ION-TTR-LRx in healthy subjects and patients with hATTR Dec. 24, 2018
Silence Therapeutics adds LP(a)-targeting siRNA medicine SLN-360 to preclinical pipeline Dec. 20, 2018
Lilly begins phase III study of tirzepatide in patients with type 2 diabetes and cardiovascular risk Dec. 20, 2018
Phase III obesity registration trial of tesofensine meets primary and secondary endpoints Dec. 18, 2018
Staten Biotechnology, Novo Nordisk enter collaboration and option agreement in hypertriglyceridemia Dec. 18, 2018
Axovant licenses gene therapies for GM1 and GM2 gangliosidosis from University of Massachusetts Dec. 17, 2018
RSS